IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roudy who wrote (1683)	8/13/1999 5:27:00 AM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

$2.4bn, now that is a serious market capitalisation. With a new high of $122 and Rituxan sales zooming and profits too, I'd like to mention again the increased value to both IDEC and TCLN shareholders and the improved prospects for Lymphoma patients if the financially powerful IDEC bought the financially strapped but technologically sound Techniclone. You must be a happy shareholder Don! What do you think of that suggestion? Rituxan is great, but why not build on the solid foundation which IDEC has created by picking up something which is in trouble but is synergistic with existing IDEC business? While IDEC is at $122, TCLN has reached again the old $1 level due to a shortage of funds for continued development according to the latest TCLN report. At the same time, they are expanding the Cotara trials [for brain glioma treatment]. Maurice PS: Here's the Cotara trial detail and the Silicon Investor discussion [not much these days]: techstocks.com The main discussion is here: clubs.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next